Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin and Paclitaxel in Advanced NSCLC
NCT00004126Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Nov 1999
- Primary completion
- Jan 2001
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in non-small cell lung cancer (NSCLC), sponsored by University of Chicago. Primary endpoint: Overall Response Rate at 4 years. Started Nov 1999; status: completed.
02
Drugs
oxaliplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00004126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004126.